<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03587142</url>
  </required_header>
  <id_info>
    <org_study_id>10- GpCRC3-BESST</org_study_id>
    <secondary_id>U01DK073983</secondary_id>
    <secondary_id>U01DK112193</secondary_id>
    <secondary_id>U01DK073975</secondary_id>
    <secondary_id>U01DK074035</secondary_id>
    <secondary_id>U01DK074007</secondary_id>
    <secondary_id>U01DK073974</secondary_id>
    <secondary_id>U24DK074008</secondary_id>
    <nct_id>NCT03587142</nct_id>
  </id_info>
  <brief_title>Buspirone for Early Satiety and Symptoms of Gastroparesis</brief_title>
  <acronym>BESST</acronym>
  <official_title>Buspirone for Early Satiety and Symptoms of Gastroparesis: A Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial (BESST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether the study medication, buspirone, an antianxiety drug, improves
      the symptoms of gastroparesis in patients with gastroparesis symptoms and at least moderately
      severe symptoms of fullness and/or inability to eat a full meal. Half the patients will
      receive buspirone and half the patients will receive a placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, double-masked, placebo-controlled, parallel treatment
      groups phase 2 trial to determine the effect of buspirone, a 5-hydroxytryptamine (5-HT) 1a
      receptor agonist, on early satiety and postprandial fullness in participants with symptoms of
      gastroparesis and with at least moderately severe symptoms of early satiety and/or
      postprandial fullness. After enrollment, participants aged 18-75 years will be treated with
      buspirone (10 mg three times per day) or a matching placebo for 4 weeks, followed by a 2-week
      post-treatment washout period. The primary outcome for the study is 4-week change (week 4
      minus baseline) in the 4-item postprandial fullness/early satiety subscore (higher scores
      indicate worse symptoms) from the Patient Assessment of Gastrointestinal Disorders Symptom
      Severity Index (PAGI-SYM) Gastroparesis Cardinal Symptom Index (GCSI). We hypothesize that
      buspirone treatment will improve symptoms of postprandial fullness/early satiety compared to
      treatment with placebo, as indicated by a lower (smaller, more negative) 4-week change in the
      postprandial fullness/early satiety subscore in the buspirone arm compared to the placebo
      arm; change for a participant will be calculated as subscore at 4-weeks minus subscore at
      baseline.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>BESST is a multi-center, randomized, placebo-controlled, double-masked, parallel treatment groups phase 2 trial with half the participants receiving the study drug, buspirone, and half receiving the placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Participants, all clinic staff and the investigators will be masked as to whether the participant is receiving buspirone or the placebo.
The study drug will be over encapsulated in a size 0 gelatin capsule with partial filler to be identical to the placebo capsule, which contains only filler.
The random treatment assignment will consist of a numbered study drug bottle; each bottle number will be unique and each participant will be assigned a specific bottle number, which is labelled: &quot;Buspirone or placebo 10 mg.&quot; with directions.
The randomization scheme will assign participants in randomly permuted blocks of assignments stratified by clinical center. The randomization plan will be prepared and administered centrally via a secure web application by the Scientific Data Research Center.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>4-Week Change in the Postprandial Fullness and Early Satiety Symptoms Severity</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>The outcome is assessed using the self-reported postprandial fullness/early satiety subscore, which is computed as the average of 4 scores for 4-items on the Gastroparesis Cardinal Symptom Index (GCSI) survey: stomach fullness, inability to finish a normal-sized meal, feeling excessively full after meals, and loss of appetite. Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the subscore ranges from 0 to 5. The change is computed as the subscore at 4-weeks minus the baseline subscore.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>4-Week Change in Total Overall GCSI Symptom Severity</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>The outcome is assessed using the self-reported total GCSI score, which is computed as the average of the 3 subscores on the GCSI survey: 3-item postprandial fullness/early satiety subscore, the nausea/vomiting subscore (average of 3-items: nausea, retching, vomiting), and bloating subscore (average of 2-items: bloating, stomach visibly larger). Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the total score ranges from 0 to 5. the change is computed as the total score at 4-weeks minus the baseline total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-Week Change in Nausea, Vomiting and Retching Symptoms Severity</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>The outcome is assessed using the self-reported nausea/vomiting subscore, which is computed as the average of 3 scores for 3-items on the GCSI survey: nausea, retching, vomiting. Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the subscore ranges from 0 to 5. The change is computed as the subscore at 4-weeks minus the baseline subscore.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-Week Change in Bloating and Stomach Distention Symptoms Severity</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>The outcome is assessed using the self-reported bloating subscore, which is computed as the average of 2 scores for 2-items on the GCSI survey: bloating, stomach visibly larger. Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the subscore ranges from 0 to 5. The change is computed as the subscore at 4-weeks minus the baseline subscore.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-Week Change in Upper Abdominal Pain and Discomfort Symptoms Severity</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>The outcome is assessed using the self-reported upper abdominal pain subscore, which is computed as the average of 2 scores for 2-items on the PAGI-SYM survey: upper abdominal pain, upper abdominal discomfort. Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the subscore ranges from 0 to 5. The change is computed as the subscore at 4-weeks minus the baseline subscore.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-Week Change in Gastroesophageal (GERD) Symptoms Severity</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>The outcome is assessed using the self-reported GERD subscore, which is computed as the average of 7 scores for 7-items on the Patient Assessment of Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM) survey: heartburn during the day, heartburn when lying down, feeling of discomfort inside chest during the day, feeling of discomfort inside chest during sleep, regurgitation or reflux during the day, regurgitation when lying down, bitter, acid or sour taste in mouth. Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the subscore ranges from 0 to 5. The change is computed as the subscore at 4-weeks minus the baseline subscore.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-Week Change in Nausea Symptom Severity</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>The outcome is assessed using self-reported assessment of nausea severity in the prior 2-weeks using the GCSI survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-Week Change in Vomiting Symptom Severity</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>The outcome is assessed using self-reported assessment of vomiting severity in the prior 2-weeks using the GCSI survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-Week Change in Stomach Fullness Symptom Severity</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>The outcome is assessed using self-reported assessment of stomach fullness severity in the prior 2-weeks using the GCSI survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-Week Change in Inability to Finish a Normal-sized Meal Symptom Severity</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>The outcome is assessed using self-reported assessment of inability to finish a normal-sized meal severity in the prior 2-weeks using the GCSI survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-Week Change in Excessive Fullness Symptom Severity</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>The outcome is assessed using self-reported assessment of feeling excessively full after meals severity in the prior 2-weeks using the GCSI survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-Week Change in Loss of Appetite Symptom Severity</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>The outcome is assessed using self-reported assessment of loss of appetite severity in the prior 2-weeks using the GCSI survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-Week Change in Bloating Symptom Severity</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>The outcome is assessed using self-reported assessment of bloating severity in the prior 2-weeks using the GCSI survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-Week Change in Upper Abdominal Pain Symptom Severity</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>The outcome is assessed using self-reported assessment of upper abdominal pain severity in the prior 2-weeks using the GCSI survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-Week Change in Gastrointestinal Symptoms Rating Scale (GSRS) Global Score</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>The outcome is assessed using the self-reported GSRS total score which is computed as the mean of the 15 item scores on the GSRS survey. Each item is scored from 1 (no discomfort) to 7 (very severe discomfort) of the symptom in the past week. The change is computed as the score at 4-weeks minus the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-Week Change in Participant's Rating of Symptom Relief</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>The outcome is assessed using the participant-rated Clinical Patient Grading Assessment Scale (CPGAS) score which is scored from -3 (very considerably worse) to 3 (completely better) in the past week compared to the way the participant usually feels. The change is computed as the score at 4-weeks minus the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-Week Change Overall Quality of Health due to Gastroparesis Issues</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>The outcome is assessed using the self-reported Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life (PAGI-QOL) total score which comprises 30 items scored from 0 (none of the time) to 5 (all of the time) the participant's QOL has been affected by their gastrointestinal issues in the prior two weeks. The total score is the mean of the 5 subscale scores and ranges from 0 (lowest QOL) to 5 (highest QOL) in past 2-weeks. The change is computed as the score at 4-weeks minus the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-Week Change in Depression</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>The outcome is assessed using the self-reported Hospital Anxiety and Depression Scale (HADS) depression subscore, calculated as the sum of 7 items, each scored from 0 (not at all) to 3 (most of the time). The change is computed as the subscore at 4-weeks minus the baseline subscore.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-Week Change in Anxiety</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>The outcome is assessed using the self-reported Hospital Anxiety and Depression Scale (HADS) anxiety subscore, calculated as the sum of 7-items, each scored from 0 (not at all) to 3 (most of the time). The change is computed as the subscore at 4-weeks minus the baseline subscore.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-Week Change in Severity of Somatic Symptoms</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>The outcome is assessed using the self-reported Patient Health Questionnaire 15 Somatic Symptom Severity Scale (PHQ-15) total somatization score, calculated as the sum of 15-items, each scored from 0 (not bothered at all) to 3 (bothered a lot) by somatic symptoms in the prior 4-weeks. The change is computed as the score at 4-weeks minus the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-Week Change in Overall Mental Quality of Life (QOL)</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>The outcome is assessed using the self-reported 36-item Short Form Health Survey (SF-36v2) mental health QOL component score. The score ranges from 0 (poorest) to 100 (highest) QOL. The change is computed as the score at 4-weeks minus the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-Week Change in Overall Physical Quality of Life (QOL)</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>The outcome is assessed using the self-reported 36-item Short Form Health Survey (SF-36v2) physical health QOL component score. The score ranges from 0 (poorest) to 100 (highest) QOL. The change is computed as the score at 4-weeks minus the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-Week Change in Gastric Retention</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>The outcome is assessed using the percent of gastric retention at 4-hours from the Gastric Emptying Scintigraphy (GES) test. The change is computed as the percent retention at 4-weeks minus the baseline percent retention.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>4-Week Change in Weight</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>This safety outcome is computed by subtracting the weight (kg) at baseline from the weight (kg) at 4-weeks</description>
  </other_outcome>
  <other_outcome>
    <measure>4-Week Cardiac Rhythm</measure>
    <time_frame>4-weeks</time_frame>
    <description>This safety outcome is computed from the results of an electrocardiogram (ECG) at 4-weeks.</description>
  </other_outcome>
  <other_outcome>
    <measure>4-Week Change in aspartate aminotransferase (ALT)</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>This safety outcome is computed by subtracting the baseline level of ALT (U/L) from the 4-week level.</description>
  </other_outcome>
  <other_outcome>
    <measure>4-Week Change in Creatinine</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>This safety outcome is computed by subtracting the baseline level of creatinine (mg/dL) from the 4-week level.</description>
  </other_outcome>
  <other_outcome>
    <measure>4-Week Change in Fasting Glucose</measure>
    <time_frame>baseline and 4-weeks</time_frame>
    <description>This safety outcome is computed by subtracting the baseline level of glucose (mg/dL) from the 4-week level.</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Symptom Side Effects over 4-Weeks</measure>
    <time_frame>over 4-weeks</time_frame>
    <description>This safety outcome is the frequency over the 4-weeks of the study of symptom side effects as reported on the 9 questions of the Symptom Side Effects survey.</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Adverse Events over 4-Weeks</measure>
    <time_frame>over 4-weeks</time_frame>
    <description>This safety outcome is the frequency over the 4-weeks of the study of all reported adverse events.</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of the Severity of Adverse Events over 4-Weeks</measure>
    <time_frame>over 4-weeks</time_frame>
    <description>This safety outcome is the frequency over the 4-weeks of the study of all reported adverse events' severity grade as classified by the NCI's Common Terminology Criteria for Adverse Events (CTCAE v5.0).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Buspirone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Buspirone HCl 10 mg capsule orally three times daily, 30 minutes before each meal, for 4-weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule orally three times daily, 30 minutes before each meal, for 4-weeks; manufactured to look identical to buspirone capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buspirone</intervention_name>
    <description>Buspirone tablet</description>
    <arm_group_label>Buspirone</arm_group_label>
    <other_name>Buspar</other_name>
    <other_name>buspirone hydrochloride (HCl)</other_name>
    <other_name>Buspar Dividose</other_name>
    <other_name>Vanspar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>&quot;Sugar&quot; pill manufactured to mimic buspirone 10 mg tablet</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo (for buspirone)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 75 years of age at initial screening interview

          -  Symptoms compatible with gastroparesis or other functional gastric disorder for at
             least 3 months (does not have to be contiguous) prior to initial screening interview

          -  Diagnosis of either diabetic or idiopathic gastroparesis

          -  Delayed or normal gastric emptying retention on screening 4-hour Gastric Emptying
             Scintigraphy test

          -  Symptoms of gastroparesis measured by the 9-item PAGI-SYM Gastroparesis Cardinal
             Symptom Index (GCSI) total score &gt; 2.0 at enrollment

          -  Symptomatic with postprandial fullness/early satiety severity at enrollment using the
             PAGI-SYM GCSI post-prandial fullness/early satiety subscore â‰¥ 3

          -  Upper endoscopy or upper GI series without ulcers or mass lesions in the 2 years prior
             to enrollment

        Exclusion Criteria:

          -  Post-surgical gastroparesis, including prior pyloromyotomy, pyloric resection,
             vagotomy, bariatric surgery or post-Nissen fundoplication

          -  Another active disorder which could explain symptoms in the opinion of the
             investigator

          -  Concurrent use of opiate narcotic analgesics more than 3 days per week

          -  Significant hepatic injury as defined by alanine aminotransferase (ALT) elevation of
             greater than twice the Upper Limit of Normal (ULN) or a Child-Pugh score of 10 or
             greater

          -  Significant renal impairment as defined by serum creatinine &gt; 3.0

          -  Uncontrolled diabetes defined as HbA1c (%) of 10% or more within 60 days of enrollment

          -  Allergy to buspirone

          -  Concurrent or prior use (within 30 days) of monoamine oxidase (MAO) inhibitors

          -  Concurrent or prior use (within 30 days) of benzodiazepines

          -  Concurrent or prior use (within 30 days) of buspirone, warfarin, haloperidol, and
             drugs to treat seizures (e.g., phenytoin and carbamazepine)

          -  Women breast feeding or known to be pregnant

          -  Any other condition, which in the opinion of the investigator would impede compliance
             or hinder completion of the study

          -  Failure to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry P Parkman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University Hospital, Philadelphia, PA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pankaj J Pasricha, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins Hospital, Baltimore, MD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SDRC Principal Investigator James /Tonascia, PhD</last_name>
    <phone>410-955-3704</phone>
    <email>jtonasc1@jhu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katherine P Yates, ScM</last_name>
    <phone>443-287-0082</phone>
    <email>kyates1@jhu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tachisha Walls, RN</last_name>
      <email>tachisha.walls@louisville.edu</email>
    </contact>
    <contact_backup>
      <last_name>Bridget Cannon</last_name>
      <email>Bridget.cannon@louisville.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Abell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Barahona</last_name>
      <email>gbaraho1@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Robert Burns</last_name>
      <email>rburns22@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Pankaj J Pasricha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>April Mendez</last_name>
      <email>Amendez5@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Casey Silvernale</last_name>
      <email>csilvernale@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Braden Kuo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anya Brown</last_name>
      <email>anybrown@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amirah Abdullah</last_name>
      <email>aamirah@wakehealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kenneth Koch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amiya Palit</last_name>
      <email>amiya.palit@temple.edu</email>
    </contact>
    <investigator>
      <last_name>Henry P Parkman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Science Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Sarosiek</last_name>
      <email>Irene.sarosiek@ttuhsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Natalia Vega</last_name>
      <email>Natalia.vega@ttuhsc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Richard W McCallum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://jhuccs1.us/gpcrc/default.asp</url>
    <description>Link to the Gastroparesis Clinical Research Consortium (GpCRC) web site Home page. There are some open-links for patients, such as Information for Patients.</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastroparesis</keyword>
  <keyword>early satiety</keyword>
  <keyword>stomach</keyword>
  <keyword>buspirone</keyword>
  <keyword>5-HT 1a receptor agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buspirone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The study will comply with the NIH Data Sharing Policy. The data will be first de-identified so that no individual participant identifiers will be included in the dataset (no names, addresses, dates, comments, etc). If a characteristic is an extreme value for this population, then those values will be categorized into one frequency group. If a CSR has multiple versions, then all data will be recoded into the format of the most current form version. A random unique identification number will be substituted for the unique BESST identification number. If a clinical item was obtained from surveys with restrictions due to licensing, then that data will be excluded. The data will be shared in 2 stages: the first will be the analytic datasets to produce the primary outcome paper. For this dataset, the documentation will include analytic code. The full dataset by CSR will be provided in the second stage.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>The analytic datasets to produce the primary result manuscript will be submitted within one year of publication of the primary result manuscript. The full clinical dataset for all Clinical Study Reports (CSRs) without proprietary restrictions will be submitted within 2 years of the primary result manuscript publication. This data will be available publicly indefinitely.</ipd_time_frame>
    <ipd_access_criteria>An investigator interested in acquiring BESST study data should contact the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Central Repository at https://www.niddkrepository.org/search/study/ and apply to obtain the data required for their study.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

